RxDoctor Payments Data

Donald Morris, MD

Nephrology · South Salt Lake, UTNPI 1306806963

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $2,000 of the $3,013 with a category attached, or 66.4%. Calliditas Therapeutics US Inc. accounts for 75.3% of it on its own, with 16 other manufacturers making up the rest. 2025 is the largest year on record at $2,389, more than ten times the $34 reported in 2019.

$3,013in general payments, 2019–2025

Across 32 payments — averaging $94.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Calliditas Therapeutics US Inc.$2K
  • AstraZeneca$175
  • Novartis$137
  • Renalytix AI, Inc.$101
  • Veloxis Pharmaceuticals, Inc.$56
  • ANI Pharmaceuticals, Inc.$46
  • plus $226 from 11 others

What the payments were for

  • Consulting fees$2,00066%
  • Food & beverage$99733%
  • Education$161%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,013 in reported general payments places this provider in the 75th percentile of 74 nephrology providers in Utah.

See all nephrology providers in Utah

Medicare billing

Part B allowed, 2024
$38,096
Medicare patients
160
Services billed
367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol11$14,638
Prednisone38$400
Carvedilol13$387
Chlorthalidone15$329
Pantoprazole Sodium12$107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$175$14,63811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 74 nephrology providers in Utah.

Other nephrology in South Salt Lake

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →